EA201990848A1 - ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2B - Google Patents
ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2BInfo
- Publication number
- EA201990848A1 EA201990848A1 EA201990848A EA201990848A EA201990848A1 EA 201990848 A1 EA201990848 A1 EA 201990848A1 EA 201990848 A EA201990848 A EA 201990848A EA 201990848 A EA201990848 A EA 201990848A EA 201990848 A1 EA201990848 A1 EA 201990848A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- imidazo
- pyridin
- ones
- substituted
- application
- Prior art date
Links
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 3
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- PGDIPOWQYRAOSK-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical class C1=CN=C2NC(=O)NC2=C1 PGDIPOWQYRAOSK-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404798P | 2016-10-06 | 2016-10-06 | |
| PCT/US2017/055278 WO2018067786A1 (en) | 2016-10-06 | 2017-10-05 | Substituted 1h-imidazo[4,5-b]pyridin-2(3h)-ones and their use as glun2b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990848A1 true EA201990848A1 (ru) | 2019-08-30 |
Family
ID=61831306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990848A EA201990848A1 (ru) | 2016-10-06 | 2017-10-05 | ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2B |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10617676B2 (https=) |
| EP (1) | EP3523311B1 (https=) |
| JP (1) | JP7001682B2 (https=) |
| KR (1) | KR20190056435A (https=) |
| CN (2) | CN110062761B (https=) |
| AR (1) | AR109810A1 (https=) |
| AU (1) | AU2017340602A1 (https=) |
| BR (1) | BR112019006691A2 (https=) |
| CA (1) | CA3038820A1 (https=) |
| CL (1) | CL2019000882A1 (https=) |
| EA (1) | EA201990848A1 (https=) |
| ES (1) | ES2950881T3 (https=) |
| IL (1) | IL265757A (https=) |
| MA (1) | MA46470A (https=) |
| MX (1) | MX2019003980A (https=) |
| PH (1) | PH12019500676A1 (https=) |
| TW (1) | TW201819376A (https=) |
| WO (1) | WO2018067786A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
| HRP20200410T1 (hr) | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| US11492345B2 (en) * | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| CN109499614B (zh) * | 2018-12-12 | 2021-06-04 | 怀化学院 | MOPs负载双齿螯合型金属催化剂及其制备方法 |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| JP7667097B2 (ja) * | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| KR20220024403A (ko) * | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| US12552797B2 (en) | 2019-11-27 | 2026-02-17 | Praxis Precision Medicines, Inc. | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine |
| AU2021233745B2 (en) * | 2020-03-11 | 2024-05-02 | Anygen Co., Ltd. | Composition for anti-diabetes and anti-obesity comprising novel compound |
| BR112022023559A2 (pt) * | 2020-05-21 | 2023-01-24 | Stemsynergy Therapeutics Inc | Inibidores de notch e seus usos |
| CN112939986B (zh) * | 2021-02-18 | 2023-06-13 | 新乡医学院 | 一种吡唑并嘧啶类化合物的合成方法 |
| KR20230037391A (ko) * | 2021-09-09 | 2023-03-16 | 애니젠 주식회사 | 신규한 화합물을 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| MX2024013240A (es) | 2022-04-26 | 2024-12-06 | Praxis Prec Medicines Inc | Tratamiento de trastornos neurologicos |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
| AU2001270149A1 (en) * | 2000-06-26 | 2002-01-08 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| EP1490364B1 (en) | 2002-03-28 | 2007-09-26 | Eisai R&D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CA2482838A1 (en) * | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| EP1720860A1 (en) | 2004-02-18 | 2006-11-15 | AstraZeneca AB | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| TWI443090B (zh) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| CN101842357A (zh) | 2007-08-30 | 2010-09-22 | 武田药品工业株式会社 | 取代的吡唑衍生物 |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS |
| WO2009118187A1 (en) | 2008-03-27 | 2009-10-01 | Evotec Neurosciences Gmbh | Methods for treating disorders using nmda nr2b-subtype selective antagonist |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| NZ590688A (en) | 2008-08-05 | 2012-09-28 | Daiichi Sankyo Co Ltd | imidazo[4,5-b]pyridin-2-one derivatives |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| CA2744498C (en) * | 2008-11-25 | 2017-10-24 | University Of Rochester | Mlk inhibitors and methods of use |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| EP2579717A4 (en) * | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 |
| JP2012188363A (ja) * | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| WO2013060029A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Allosteric modulators of metabotropic glutamate receptors |
| WO2013130855A1 (en) | 2012-03-02 | 2013-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| SG11201506687RA (en) | 2013-03-15 | 2015-09-29 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| CA2918242C (en) | 2013-07-31 | 2022-06-21 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| WO2016015097A1 (en) | 2014-07-28 | 2016-02-04 | Safemate Australia Pty Ltd | Systems and methods for making personal emergency information available to third parties |
| ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
| WO2016025917A1 (en) | 2014-08-15 | 2016-02-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| US12006328B2 (en) | 2014-11-18 | 2024-06-11 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto |
| MA41803A (fr) | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| HRP20200410T1 (hr) * | 2015-07-09 | 2020-08-21 | Janssen Pharmaceutica Nv | Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora |
| BR112018016329A2 (pt) | 2016-02-10 | 2018-12-18 | Janssen Pharmaceutica Nv | 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| IL271149B2 (en) | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| WO2019193516A2 (en) | 2018-04-04 | 2019-10-10 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators |
| CN110294756A (zh) | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| SG11202112405VA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
| CN113950357A (zh) | 2019-06-14 | 2022-01-18 | 詹森药业有限公司 | 吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途 |
| KR20220024403A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도 |
| AU2020293642A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
| CN113993868A (zh) | 2019-06-14 | 2022-01-28 | 詹森药业有限公司 | 取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途 |
-
2017
- 2017-10-03 TW TW106134127A patent/TW201819376A/zh unknown
- 2017-10-05 US US15/725,500 patent/US10617676B2/en active Active
- 2017-10-05 JP JP2019518219A patent/JP7001682B2/ja active Active
- 2017-10-05 MX MX2019003980A patent/MX2019003980A/es unknown
- 2017-10-05 CN CN201780075930.5A patent/CN110062761B/zh active Active
- 2017-10-05 CN CN202210460371.2A patent/CN114989164B/zh active Active
- 2017-10-05 AU AU2017340602A patent/AU2017340602A1/en not_active Abandoned
- 2017-10-05 WO PCT/US2017/055278 patent/WO2018067786A1/en not_active Ceased
- 2017-10-05 ES ES17859165T patent/ES2950881T3/es active Active
- 2017-10-05 CA CA3038820A patent/CA3038820A1/en active Pending
- 2017-10-05 EP EP17859165.7A patent/EP3523311B1/en active Active
- 2017-10-05 MA MA046470A patent/MA46470A/fr unknown
- 2017-10-05 BR BR112019006691A patent/BR112019006691A2/pt not_active Application Discontinuation
- 2017-10-05 AR ARP170102779A patent/AR109810A1/es unknown
- 2017-10-05 EA EA201990848A patent/EA201990848A1/ru unknown
- 2017-10-05 KR KR1020197012678A patent/KR20190056435A/ko not_active Withdrawn
-
2019
- 2019-03-28 PH PH12019500676A patent/PH12019500676A1/en unknown
- 2019-04-01 IL IL265757A patent/IL265757A/en unknown
- 2019-04-02 CL CL2019000882A patent/CL2019000882A1/es unknown
-
2020
- 2020-03-03 US US16/807,385 patent/US11207298B2/en not_active Expired - Fee Related
-
2021
- 2021-09-14 US US17/474,631 patent/US11759455B2/en active Active
-
2023
- 2023-06-29 US US18/344,169 patent/US20230338341A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3523311B1 (en) | 2023-06-07 |
| MX2019003980A (es) | 2019-06-10 |
| WO2018067786A1 (en) | 2018-04-12 |
| US20230000833A1 (en) | 2023-01-05 |
| JP2019530695A (ja) | 2019-10-24 |
| CN110062761B (zh) | 2022-05-13 |
| CN114989164A (zh) | 2022-09-02 |
| PH12019500676A1 (en) | 2019-12-02 |
| EP3523311A4 (en) | 2020-03-18 |
| US10617676B2 (en) | 2020-04-14 |
| TW201819376A (zh) | 2018-06-01 |
| US20210069155A1 (en) | 2021-03-11 |
| JP7001682B2 (ja) | 2022-01-19 |
| EP3523311C0 (en) | 2023-06-07 |
| CN110062761A (zh) | 2019-07-26 |
| CL2019000882A1 (es) | 2019-06-21 |
| IL265757A (en) | 2019-06-30 |
| AR109810A1 (es) | 2019-01-23 |
| CN114989164B (zh) | 2024-08-13 |
| EP3523311A1 (en) | 2019-08-14 |
| AU2017340602A1 (en) | 2019-04-18 |
| US20230338341A1 (en) | 2023-10-26 |
| US20180125826A1 (en) | 2018-05-10 |
| US11207298B2 (en) | 2021-12-28 |
| MA46470A (fr) | 2019-08-14 |
| US11759455B2 (en) | 2023-09-19 |
| ES2950881T3 (es) | 2023-10-16 |
| CA3038820A1 (en) | 2018-04-12 |
| BR112019006691A2 (pt) | 2019-06-25 |
| KR20190056435A (ko) | 2019-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990848A1 (ru) | ЗАМЕЩЕННЫЕ 1H-ИМИДАЗО[4,5-b]ПИРИДИН-2(3H)-ОНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА GLUN2B | |
| SA521422031B1 (ar) | مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين | |
| EA201890245A1 (ru) | Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b | |
| EA201891799A1 (ru) | Замещенные 1,2,3-триазолы в качестве nr2b-селективных модуляторов nmda | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| NZ737399A (en) | Ccr2 modulators | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| CO2021016860A2 (es) | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b | |
| EA201491520A1 (ru) | НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| MX2021015510A (es) | Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b. | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| MX2021015506A (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b. | |
| WO2019193516A3 (en) | Substituted pyridine and pyrimidines and their use as glun2b receptor modulators | |
| EA201691413A1 (ru) | Селективные антагонисты nr2b | |
| EA201891710A1 (ru) | Терапевтические соединения | |
| EA201790427A1 (ru) | Замещенные бициклические соединения | |
| PH12016501393B1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
| BR112016004904A8 (pt) | moduladores de receptor x do fígado (lxr), composição farmacêutica, seus usos e método para modular atividade de lxr | |
| EA201890946A1 (ru) | Селективные антагонисты nr2b | |
| EA201790795A1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| PH12021552838A1 (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators | |
| PH12021552839A1 (en) | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |